- Trials with a EudraCT protocol (32)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
32 result(s) found for: Rule of Six.
Displaying page 1 of 2.
EudraCT Number: 2013-001838-17 | Sponsor Protocol Number: MV140-SLG-003 | Start Date*: 2015-07-17 | |||||||||||
Sponsor Name:Inmunotek, S.L. [...] | |||||||||||||
Full Title: PROSPECTIVE MULTICENTER CLINICAL TRIAL RANDOMIZED, DOUBLE-BLIND, PARALLEL-CONTROLLED VERSUS PLACEBO IN A POLYVALENT SUBLINGUAL BACTERIAL VACCINE (IN ORAL MUCOSA) TO THREE MONTHS AND SIX MONTHS IN ... | |||||||||||||
Medical condition: Recurrent Urinary Tract Infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: ES (Ongoing) GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016678-34 | Sponsor Protocol Number: CRO1456 | Start Date*: 2010-04-15 |
Sponsor Name:Imperial College London | ||
Full Title: Exploring the Relationship Between Insulin Resistance and Interferon Resistance: Options to Overcome HCV Non-Response to Pegylated Interferon | ||
Medical condition: HCV infected patient who do not response to Pegylated Interferon. This study is trying to explore the relationship between insulin resistance and Interferon Resistance and the possible rule of Pio... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2022-001522-30 | Sponsor Protocol Number: RIMOFATSCI-2 | Start Date*: 2022-10-03 |
Sponsor Name:Fundación Hospital Nacional de Parapléjicos | ||
Full Title: Effects of a CB1 receptor reverse antagonist/agonist (Rimonabant) on wandering ability in patients with incomplete spinal cord injuries | ||
Medical condition: Possibility of improving wandering in patients. The effects of Rimonabant on other functional measures will be assessed and it will be confirmed that it is a safe treatment in the study population. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002011-33 | Sponsor Protocol Number: PROGRESS | Start Date*: 2017-08-28 | |||||||||||
Sponsor Name:Hellenic Institute for the Study of Sepsis | |||||||||||||
Full Title: A RANDOMIZED PROSPECTIVE CLINICAL TRIAL TO ASSESS THE ROLE OF PROCALCITONIN-GUIDED ANTIMICROBIAL THERAPY TO REDUCE LONG-TERM INFECTIONS SEQUELAE | |||||||||||||
Medical condition: USE OF PROCALCITONIN IN EARLY STOP OF ANTIBIOTICS TO AVOID LONG-TERM CONSEQUENCES | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002511-26 | Sponsor Protocol Number: 08062019 | Start Date*: 2019-12-20 | |||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||
Full Title: Repeated Injection Therapy of Allogeneic Stem Cells in Ischemic No-option Patients - A Multi-Centre Study (SCIENCE REPEAT) | |||||||||||||
Medical condition: Ischemic heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000870-63 | Sponsor Protocol Number: WV19432 | Start Date*: 2007-03-01 | |||||||||||
Sponsor Name:F.Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A phase IV, 2x2 factorial, double blind study of 24 versus 48 weeks and 90 versus 180 mcg doses of pegylated interferon alfa 2a 40KD (PEG IFN, Ro 25-8310) in adult patients with HBeAg positive chro... | |||||||||||||
Medical condition: Chronic hepatitis B | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004823-39 | Sponsor Protocol Number: CC-5013-MM-020/IFM 07-01 | Start Date*: 2008-04-03 | |||||||||||
Sponsor Name:Celgene Corporation | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, OPEN-LABEL, 3-ARM STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE (REVLIMID) PLUS LOW-DOSE DEXAMETHASONE WHEN GIVEN UNTIL PROGRESSIVE DISEASE OR FOR 18 FOUR-WEEK... | |||||||||||||
Medical condition: Previously untreated multiple myeloma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Completed) IE (Prematurely Ended) IT (Completed) AT (Completed) ES (Completed) SE (Completed) BE (Completed) PT (Completed) DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014815-11 | Sponsor Protocol Number: E6201-E044-204 | Start Date*: 2010-03-10 | |||||||||||
Sponsor Name:Eisai Limited | |||||||||||||
Full Title: A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects with Psoriasis Vulgaris | |||||||||||||
Medical condition: Chronic stable plaque psoriasis with one or two stable psoriatic plaque(s) suitable in size and location for five separate treatment fields to be assessed within it. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019884-12 | Sponsor Protocol Number: INFIRE-001 | Start Date*: 2010-12-17 | |||||||||||
Sponsor Name:Universitätsklinikum Aachen | |||||||||||||
Full Title: Induction of Fibrosis Regression regarding Chronic Hepatitis B Infection | |||||||||||||
Medical condition: Patients with chronic hepatitis B infection and a relevant grade of fibrosis (histological >= F2) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004743-22 | Sponsor Protocol Number: FFR30006 | Start Date*: Information not available in EudraCT |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc... | ||
Medical condition: Vasomotor/Idiopathic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-004744-43 | Sponsor Protocol Number: FFR30007 | Start Date*: Information not available in EudraCT |
Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mc... | ||
Medical condition: Vasomotor/Idiopathic Rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) CZ (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-004888-37 | Sponsor Protocol Number: FFR111158 | Start Date*: 2016-08-03 |
Sponsor Name:GlaxoSmithKline Research and Development Ltd | ||
Full Title: A Pilot, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study to Evaluate the Efficacy and Safety of Once-daily Intranasal Administration of Fluticasone Furoate Nasal Spr... | ||
Medical condition: Irritant (non-allergic) rhinitis | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2006-006465-16 | Sponsor Protocol Number: rhGH in MS | Start Date*: Information not available in EudraCT | ||||||||||||||||
Sponsor Name:University of Leipzig | ||||||||||||||||||
Full Title: Pilot trial of recombinant human growth hormone for remyelination in multiple sclerosis | ||||||||||||||||||
Medical condition: Multiple Sclerosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001560-19 | Sponsor Protocol Number: CSCC-ASC2 | Start Date*: 2015-06-29 | |||||||||||
Sponsor Name:Department of Cardiology, Rigshospitalet | |||||||||||||
Full Title: Allogeneic adipose tissue-derived stromal/stem cell therapy in patients with ischemic heart disease and heart failure | |||||||||||||
Medical condition: Ischemic heart disease and heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000230-35 | Sponsor Protocol Number: 014-FPO18 | Start Date*: 2018-10-17 | |||||||||||
Sponsor Name:FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCCS | |||||||||||||
Full Title: Phase II study on the combination of trabectedin and olaparib for advanced, platinum-resistant ovarian/tubes and primary of peritoneum cancer. - TROOPS trial (TRabectedin plus Olaparib in advanced ... | |||||||||||||
Medical condition: platinum-resistant ovarian carcinoma or Fallopian tubes or primary of peritoneum | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000214-71 | Sponsor Protocol Number: NAK-03 | Start Date*: 2008-07-01 | |||||||||||
Sponsor Name:Laboratorios Menarini S.A. (Menarini Group) | |||||||||||||
Full Title: Double blind, randomized, placebo-controlled, parallel group study to evaluate the effect of a 4-week treatment with oral doses of MEN15596 in irritable bowel syndrome. | |||||||||||||
Medical condition: Irritable Bowel Syndrome. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) SK (Completed) LV (Completed) DE (Completed) DK (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022253-42 | Sponsor Protocol Number: CTU10.041/BRd | Start Date*: 2012-02-14 | |||||||||||
Sponsor Name:Kantonsspital St. Gallen | |||||||||||||
Full Title: An open, multicentric phase II trial to evaluate the efficacy and safety of Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line therapy for patients with relapsed or refracto... | |||||||||||||
Medical condition: First relapsed or refractory multiple myeloma (including relapse after high dose chemotherapy followed by autologous stem cell transplantation) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002929-19 | Sponsor Protocol Number: SCIENCE | Start Date*: 2017-01-17 | |||||||||||
Sponsor Name:Department of Cardiology, Rigshospitalet | |||||||||||||
Full Title: Stem Cell therapy in IschEmic Non-treatable Cardiac disease - SCIENCE | |||||||||||||
Medical condition: Ischemic heart disease and heart failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) DK (Completed) SI (Completed) DE (Ongoing) AT (Ongoing) PL (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-003020-32 | Sponsor Protocol Number: A011-16 | Start Date*: 2022-02-03 | |||||||||||
Sponsor Name:Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA | |||||||||||||
Full Title: Phase 2, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effects of Sotatercept versus Placebo-Controlled for the Treatment of Combined Postcapillary and Precapillary Pulmonary ... | |||||||||||||
Medical condition: Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved Ejection Fraction (HFpEF) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned) SE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004281-28 | Sponsor Protocol Number: POLARIS2015-003 | Start Date*: 2017-01-23 | |||||||||||
Sponsor Name:Polaris Pharmaceuticals, Inc. | |||||||||||||
Full Title: Randomized, Double-Blind, Phase 2/3 Study in Subjects with Malignant Pleural Mesothelioma to Assess ADI-PEG 20 with Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) | |||||||||||||
Medical condition: Advanced malignant pleural mesothelioma (MPM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
